EVOK Evoke Pharma Inc revenue, earnings and financials
For the quarter ended September 30, 2025, Evoke Pharma Inc reported revenue of $4.28M (up 61.4% from a year earlier), net income of −$1.16M and diluted EPS of −$0.45; over the last four quarters revenue was $14.4M and net income −$5.23M; for the fiscal year ended December 2024 revenue was $10.2M, up 97.8% on the year before.
EVOK annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $10.2M, gross profit n/a, operating income −$5.20M, net income −$5.35M (margin -52.2%), EPS −$2.81
- Fiscal year ended Dec 2023: revenue $5.18M, gross profit n/a, operating income −$7.43M, net income −$7.79M (margin -150.4%), EPS −$27.97
- Fiscal year ended Dec 2022: revenue $2.51M, gross profit n/a, operating income −$7.79M, net income −$5.35M (margin -213.3%), EPS −$2.62
- Fiscal year ended Dec 2021: revenue $1.62M, gross profit n/a, operating income −$8.15M, net income −$8.54M (margin -527.7%), EPS −$3.18
EVOK quarterly revenue and earnings
- Quarter ended Sep 30, 2025: revenue $4.28M (up 61.4% year over year), net income −$1.16M, EPS −$0.45
- Quarter ended Jun 30, 2025: revenue $3.75M (up 47.1% year over year), net income −$1.57M, EPS −$0.62
- Quarter ended Mar 31, 2025: revenue $3.08M (up 77.5% year over year), net income −$1.31M, EPS −$0.51
- Quarter ended Dec 31, 2024 (from the annual report): revenue $3.31M (up 97.4% year over year), net income −$1.19M, EPS $1.15
- Quarter ended Sep 30, 2024: revenue $2.65M (up 69.8% year over year), net income −$1.31M, EPS −$0.94
- Quarter ended Jun 30, 2024: revenue $2.55M (up 125.5% year over year), net income −$1.27M, EPS −$0.93
- Quarter ended Mar 31, 2024: revenue $1.74M (up 114.2% year over year), net income −$1.58M, EPS −$2.09
- Quarter ended Dec 31, 2023 (from the annual report): revenue $1.68M (up 110.5% year over year), net income −$2.28M, EPS −$14.51
- Quarter ended Sep 30, 2023: revenue $1.56M (up 87.8% year over year), net income −$1.69M, EPS −$6.08
- Quarter ended Jun 30, 2023: revenue $1.13M (up 145.0% year over year), net income −$1.58M, EPS −$6.71
- Quarter ended Mar 31, 2023: revenue $810K (up 93.7% year over year), net income −$2.24M, EPS −$0.67
- Quarter ended Dec 31, 2022 (from the annual report): revenue $796K (up 120.9% year over year), net income $1.07M, EPS −$0.51
- Quarter ended Sep 30, 2022: revenue $832K (down 10.6% year over year), net income −$2.01M, EPS −$0.60
- Quarter ended Jun 30, 2022: revenue $462K (up 95.2% year over year), net income −$2.23M, EPS −$0.71
- Quarter ended Mar 31, 2022: revenue $418K (up 362.7% year over year), net income −$2.17M, EPS −$0.80
- Quarter ended Dec 31, 2021 (from the annual report): revenue $361K, net income −$1.67M, EPS −$1.52
- Quarter ended Sep 30, 2021: revenue $930K, net income −$1.97M, EPS −$0.73
- Quarter ended Jun 30, 2021: revenue $237K, net income −$2.29M, EPS −$0.85
- Quarter ended Mar 31, 2021: revenue $90.4K, net income −$2.61M, EPS −$0.08
EVOK cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$5.46M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$4.98M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$6.60M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$12.4M, share buybacks n/a
EVOK balance sheet
- Sep 30, 2025: cash $11.6M, total assets $15.6M, total liabilities $12.3M, shareholders' equity $3.36M
- Jun 30, 2025: cash $12.1M, total assets $16.1M, total liabilities $11.7M, shareholders' equity $4.37M
- Mar 31, 2025: cash $12.6M, total assets $16.4M, total liabilities $10.5M, shareholders' equity $5.84M
- Dec 31, 2024: cash $13.6M, total assets $17.5M, total liabilities $10.5M, shareholders' equity $7.04M
- Sep 30, 2024: cash $11.3M, total assets $14.2M, total liabilities $9.77M, shareholders' equity $4.39M
- Jun 30, 2024: cash $9.18M, total assets $12.1M, total liabilities $9.47M, shareholders' equity $2.66M
- Mar 31, 2024: cash $9.70M, total assets $12.5M, total liabilities $8.96M, shareholders' equity $3.50M
- Dec 31, 2023: cash $4.74M, total assets $7.07M, total liabilities $9.65M, shareholders' equity −$2.58M
What is EVOK's revenue?
Evoke Pharma Inc reported $14.4M of revenue over its last four quarters, through September 30, 2025.
Is EVOK profitable?
No. Evoke Pharma Inc lost $5.23M over the last four quarters.
What is EVOK's EPS?
Diluted earnings per share over the last four quarters were −$0.43; −$0.45 in the latest quarter.